Comparative effectiveness of switching to natalizumab or fingolimod after relapse on first-line relapsing-remetting multiple sclerosis therapy: propensity score matching analysis from the MSBase registry

Spelman T., Havrdova E., Horakova D., Izquierdo G., Kalincik T., Lugaresi A., ...More

34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, Berlin, Germany, 10 - 12 October 2018, pp.31

  • Publication Type: Conference Paper / Full Text
  • City: Berlin
  • Country: Germany
  • Page Numbers: pp.31
  • Dokuz Eylül University Affiliated: Yes